Prognostic significance of fever-induced Brugada syndrome

Yuka Mizusawa, Hiroshi Morita, Arnon Adler, Ofer Havakuk, Aurélie Thollet, Philippe Maury, Dao W. Wang, Kui Hong, Estelle Gandjbakhch, Frédéric Sacher, Dan Hu, Ahmad S. Amin, Najim Lahrouchi, Hanno L. Tan, Charles Antzelevitch, Vincent Probst, Sami Viskin, Arthur A M Wilde

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Background: In Brugada syndrome (BrS), spontaneous type 1 electrocardiogram (ECG) is an established risk marker for fatal arrhythmias whereas drug-induced type 1 ECG shows a relatively benign prognosis. No study has analyzed the prognosis of fever-induced type 1 ECG (F-type1) in a large BrS cohort. Objectives: The objectives of this study were to assess the prognosis of F-type1 in asymptomatic BrS and to compare the effects of fever and drugs on ECG parameters. Methods: One hundred twelve patients with BrS who developed F-type1 were retrospectively enrolled. Prognosis was evaluated in 88 asymptomatic patients. In a subgroup (n = 52), ECG parameters of multiple ECGs (at baseline, during fever, and after drug challenge) were analyzed. Results: Eighty-eight asymptomatic patients had a mean age of 45.8 ± 18.7 years, and 71.6% (67 of 88) were men. Twenty-one percent (18 of 88) had a family history of sudden cardiac death, and 26.4% (14 of 53) carried a pathogenic SCN5A mutation. Drug challenge was positive in 29 of 36 patients tested (80.6%). The risk of ventricular fibrillation in asymptomatic patients was 0.9%/y (3 of 88; 43.6 ± 37.4 months). ST-segment elevation in lead V2 during fever and after drug challenge was not significantly different (0.41 ± 0.21 ms during fever and 0.40 ± 0.30 ms after drug challenge; P > .05). Fever shortened the PR interval compared to baseline, whereas drug challenge resulted in prolonged PR interval and QRS duration (PR interval: 169 ± 29 ms at baseline, 148 ± 45 ms during fever, and 202 ± 35 ms after drug challenge; QRS duration: 97 ± 18 ms at baseline, 92 ± 28 ms during fever, and 117 ± 21 ms after drug challenge). Conclusion: Patients with BrS who develop F-type1 are at risk of arrhythmic events. F-type1 appears to develop through a more complex mechanism as compared with drug-induced type 1 ECG.

Original languageEnglish
JournalHeart Rhythm
DOIs
Publication statusAccepted/In press - 2016

Fingerprint

Brugada Syndrome
Fever
Electrocardiography
Pharmaceutical Preparations
Sudden Cardiac Death
Ventricular Fibrillation
Cardiac Arrhythmias

Keywords

  • Brugada syndrome
  • Drug-induced type 1 ECG
  • Fever-induced type 1 ECG
  • Prognosis

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Physiology (medical)

Cite this

Mizusawa, Y., Morita, H., Adler, A., Havakuk, O., Thollet, A., Maury, P., ... Wilde, A. A. M. (Accepted/In press). Prognostic significance of fever-induced Brugada syndrome. Heart Rhythm. https://doi.org/10.1016/j.hrthm.2016.03.044

Prognostic significance of fever-induced Brugada syndrome. / Mizusawa, Yuka; Morita, Hiroshi; Adler, Arnon; Havakuk, Ofer; Thollet, Aurélie; Maury, Philippe; Wang, Dao W.; Hong, Kui; Gandjbakhch, Estelle; Sacher, Frédéric; Hu, Dan; Amin, Ahmad S.; Lahrouchi, Najim; Tan, Hanno L.; Antzelevitch, Charles; Probst, Vincent; Viskin, Sami; Wilde, Arthur A M.

In: Heart Rhythm, 2016.

Research output: Contribution to journalArticle

Mizusawa, Y, Morita, H, Adler, A, Havakuk, O, Thollet, A, Maury, P, Wang, DW, Hong, K, Gandjbakhch, E, Sacher, F, Hu, D, Amin, AS, Lahrouchi, N, Tan, HL, Antzelevitch, C, Probst, V, Viskin, S & Wilde, AAM 2016, 'Prognostic significance of fever-induced Brugada syndrome', Heart Rhythm. https://doi.org/10.1016/j.hrthm.2016.03.044
Mizusawa, Yuka ; Morita, Hiroshi ; Adler, Arnon ; Havakuk, Ofer ; Thollet, Aurélie ; Maury, Philippe ; Wang, Dao W. ; Hong, Kui ; Gandjbakhch, Estelle ; Sacher, Frédéric ; Hu, Dan ; Amin, Ahmad S. ; Lahrouchi, Najim ; Tan, Hanno L. ; Antzelevitch, Charles ; Probst, Vincent ; Viskin, Sami ; Wilde, Arthur A M. / Prognostic significance of fever-induced Brugada syndrome. In: Heart Rhythm. 2016.
@article{f081853c1c654236a4a27c7d2482a185,
title = "Prognostic significance of fever-induced Brugada syndrome",
abstract = "Background: In Brugada syndrome (BrS), spontaneous type 1 electrocardiogram (ECG) is an established risk marker for fatal arrhythmias whereas drug-induced type 1 ECG shows a relatively benign prognosis. No study has analyzed the prognosis of fever-induced type 1 ECG (F-type1) in a large BrS cohort. Objectives: The objectives of this study were to assess the prognosis of F-type1 in asymptomatic BrS and to compare the effects of fever and drugs on ECG parameters. Methods: One hundred twelve patients with BrS who developed F-type1 were retrospectively enrolled. Prognosis was evaluated in 88 asymptomatic patients. In a subgroup (n = 52), ECG parameters of multiple ECGs (at baseline, during fever, and after drug challenge) were analyzed. Results: Eighty-eight asymptomatic patients had a mean age of 45.8 ± 18.7 years, and 71.6{\%} (67 of 88) were men. Twenty-one percent (18 of 88) had a family history of sudden cardiac death, and 26.4{\%} (14 of 53) carried a pathogenic SCN5A mutation. Drug challenge was positive in 29 of 36 patients tested (80.6{\%}). The risk of ventricular fibrillation in asymptomatic patients was 0.9{\%}/y (3 of 88; 43.6 ± 37.4 months). ST-segment elevation in lead V2 during fever and after drug challenge was not significantly different (0.41 ± 0.21 ms during fever and 0.40 ± 0.30 ms after drug challenge; P > .05). Fever shortened the PR interval compared to baseline, whereas drug challenge resulted in prolonged PR interval and QRS duration (PR interval: 169 ± 29 ms at baseline, 148 ± 45 ms during fever, and 202 ± 35 ms after drug challenge; QRS duration: 97 ± 18 ms at baseline, 92 ± 28 ms during fever, and 117 ± 21 ms after drug challenge). Conclusion: Patients with BrS who develop F-type1 are at risk of arrhythmic events. F-type1 appears to develop through a more complex mechanism as compared with drug-induced type 1 ECG.",
keywords = "Brugada syndrome, Drug-induced type 1 ECG, Fever-induced type 1 ECG, Prognosis",
author = "Yuka Mizusawa and Hiroshi Morita and Arnon Adler and Ofer Havakuk and Aur{\'e}lie Thollet and Philippe Maury and Wang, {Dao W.} and Kui Hong and Estelle Gandjbakhch and Fr{\'e}d{\'e}ric Sacher and Dan Hu and Amin, {Ahmad S.} and Najim Lahrouchi and Tan, {Hanno L.} and Charles Antzelevitch and Vincent Probst and Sami Viskin and Wilde, {Arthur A M}",
year = "2016",
doi = "10.1016/j.hrthm.2016.03.044",
language = "English",
journal = "Heart Rhythm",
issn = "1547-5271",
publisher = "Elsevier",

}

TY - JOUR

T1 - Prognostic significance of fever-induced Brugada syndrome

AU - Mizusawa, Yuka

AU - Morita, Hiroshi

AU - Adler, Arnon

AU - Havakuk, Ofer

AU - Thollet, Aurélie

AU - Maury, Philippe

AU - Wang, Dao W.

AU - Hong, Kui

AU - Gandjbakhch, Estelle

AU - Sacher, Frédéric

AU - Hu, Dan

AU - Amin, Ahmad S.

AU - Lahrouchi, Najim

AU - Tan, Hanno L.

AU - Antzelevitch, Charles

AU - Probst, Vincent

AU - Viskin, Sami

AU - Wilde, Arthur A M

PY - 2016

Y1 - 2016

N2 - Background: In Brugada syndrome (BrS), spontaneous type 1 electrocardiogram (ECG) is an established risk marker for fatal arrhythmias whereas drug-induced type 1 ECG shows a relatively benign prognosis. No study has analyzed the prognosis of fever-induced type 1 ECG (F-type1) in a large BrS cohort. Objectives: The objectives of this study were to assess the prognosis of F-type1 in asymptomatic BrS and to compare the effects of fever and drugs on ECG parameters. Methods: One hundred twelve patients with BrS who developed F-type1 were retrospectively enrolled. Prognosis was evaluated in 88 asymptomatic patients. In a subgroup (n = 52), ECG parameters of multiple ECGs (at baseline, during fever, and after drug challenge) were analyzed. Results: Eighty-eight asymptomatic patients had a mean age of 45.8 ± 18.7 years, and 71.6% (67 of 88) were men. Twenty-one percent (18 of 88) had a family history of sudden cardiac death, and 26.4% (14 of 53) carried a pathogenic SCN5A mutation. Drug challenge was positive in 29 of 36 patients tested (80.6%). The risk of ventricular fibrillation in asymptomatic patients was 0.9%/y (3 of 88; 43.6 ± 37.4 months). ST-segment elevation in lead V2 during fever and after drug challenge was not significantly different (0.41 ± 0.21 ms during fever and 0.40 ± 0.30 ms after drug challenge; P > .05). Fever shortened the PR interval compared to baseline, whereas drug challenge resulted in prolonged PR interval and QRS duration (PR interval: 169 ± 29 ms at baseline, 148 ± 45 ms during fever, and 202 ± 35 ms after drug challenge; QRS duration: 97 ± 18 ms at baseline, 92 ± 28 ms during fever, and 117 ± 21 ms after drug challenge). Conclusion: Patients with BrS who develop F-type1 are at risk of arrhythmic events. F-type1 appears to develop through a more complex mechanism as compared with drug-induced type 1 ECG.

AB - Background: In Brugada syndrome (BrS), spontaneous type 1 electrocardiogram (ECG) is an established risk marker for fatal arrhythmias whereas drug-induced type 1 ECG shows a relatively benign prognosis. No study has analyzed the prognosis of fever-induced type 1 ECG (F-type1) in a large BrS cohort. Objectives: The objectives of this study were to assess the prognosis of F-type1 in asymptomatic BrS and to compare the effects of fever and drugs on ECG parameters. Methods: One hundred twelve patients with BrS who developed F-type1 were retrospectively enrolled. Prognosis was evaluated in 88 asymptomatic patients. In a subgroup (n = 52), ECG parameters of multiple ECGs (at baseline, during fever, and after drug challenge) were analyzed. Results: Eighty-eight asymptomatic patients had a mean age of 45.8 ± 18.7 years, and 71.6% (67 of 88) were men. Twenty-one percent (18 of 88) had a family history of sudden cardiac death, and 26.4% (14 of 53) carried a pathogenic SCN5A mutation. Drug challenge was positive in 29 of 36 patients tested (80.6%). The risk of ventricular fibrillation in asymptomatic patients was 0.9%/y (3 of 88; 43.6 ± 37.4 months). ST-segment elevation in lead V2 during fever and after drug challenge was not significantly different (0.41 ± 0.21 ms during fever and 0.40 ± 0.30 ms after drug challenge; P > .05). Fever shortened the PR interval compared to baseline, whereas drug challenge resulted in prolonged PR interval and QRS duration (PR interval: 169 ± 29 ms at baseline, 148 ± 45 ms during fever, and 202 ± 35 ms after drug challenge; QRS duration: 97 ± 18 ms at baseline, 92 ± 28 ms during fever, and 117 ± 21 ms after drug challenge). Conclusion: Patients with BrS who develop F-type1 are at risk of arrhythmic events. F-type1 appears to develop through a more complex mechanism as compared with drug-induced type 1 ECG.

KW - Brugada syndrome

KW - Drug-induced type 1 ECG

KW - Fever-induced type 1 ECG

KW - Prognosis

UR - http://www.scopus.com/inward/record.url?scp=84965041821&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84965041821&partnerID=8YFLogxK

U2 - 10.1016/j.hrthm.2016.03.044

DO - 10.1016/j.hrthm.2016.03.044

M3 - Article

JO - Heart Rhythm

JF - Heart Rhythm

SN - 1547-5271

ER -